Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Why Sarepta Therapeutics' Q3 Was Better Than Expected

TheMotleyFool

0 0

Why Sarepta Therapeutics' Q3 Was Better Than ExpectedPhoto, wide shot, wide-angle lens, Clinical research organization, sunset photo at golden hour, photo by Peter Lik: https://img.midjourneyapi.xyz/temp/02f7778c-d723-4fb3-bdef-fabb7e5fc9c8.png

Sarepta Therapeutics (NASDAQ: SRPT) was once a high-flying biotech stock. That was before the Food and Drug Administration (FDA) surprisingly rejected approval of the Duchenne muscular dystrophy (DMD) drug golodirsen in August.

The company announced its third-quarter results after the market closed on Thursday. While there wasn't enough great news for Sarepta to return to its previous high-flying ways, the results were pretty good. Here are the highlights from the biotech's Q3 update.

Image Source: Getty Images.

Source Fool.com

Like: 0

SRPT

Teilen